Systemic sclerosis associated pulmonary hypertension: improved survival in the current era. - Wikidata - thesis-toulmin - TriplyDB

Systemic sclerosis associated pulmonary hypertension: improved survival in the current era.

Systemic sclerosis associated pulmonary hypertension: improved survival in the current era.

http://www.wikidata.org/entity/Q35771091

about

My approach to the treatment of scleroderma Selective endothelin A receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease Multicentre randomised placebo-controlled trial of oral anticoagulation with apixaban in systemic sclerosis-related pulmonary arterial hypertension: the SPHInX study protocol Systemic sclerosis-associated pulmonary arterial hypertension Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Pulmonary arterial hypertension associated with connective tissue diseases Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension.How should we treat vascular and fibrotic lung disease in scleroderma?Integrated care and optimal management of pulmonary arterial hypertension Lung involvement in systemic sclerosis.Vascular involvement in systemic sclerosis (scleroderma).Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions.Surrogate end points in pulmonary arterial hypertension: assessing the response to therapy.Changes in causes of death in systemic sclerosis, 1972-2002 Pulmonary arterial hypertension in connective tissue diseases.In search of markers of treatment failure and poor prognosis in IPAH - the value of mosaic lung attenuation pattern on thin-section CT scans.Pulmonary hypertension in parenchymal lung disease.Bosentan for the treatment of systemic sclerosis-associated pulmonary arterial hypertension, pulmonary fibrosis and digital ulcers.Review of bosentan in the management of pulmonary arterial hypertension Predictors of mortality in connective tissue disease-associated pulmonary arterial hypertension: a cohort study.Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype.Update on pathophysiology of scleroderma with special reference to immunoinflammatory events.New therapeutic strategies in the management of systemic sclerosis.Pulmonary Arterial Hypertension-A Deadly Complication of Systemic Sclerosis.Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter?Pulmonary arterial hypertension in systemic sclerosis: the need for early detection and treatment.Bosentan regulates the expression of adhesion molecules on circulating T cells and serum soluble adhesion molecules in systemic sclerosis-associated pulmonary arterial hypertension Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases.Systemic sclerosis: an update for clinicians.Therapies for scleroderma-related pulmonary arterial hypertension Prevalence of Pulmonary Arterial Hypertension in Korean Adult Patients with Systemic Sclerosis: Result of a Pilot Echocardiographic Screening Study.At the heart of tissue: endothelin system and end-organ damage.Bosentan for the treatment of adult pulmonary hypertension.Review series: Aspects of interstitial lung disease: connective tissue disease-associated interstitial lung disease: how does it differ from IPF? How should the clinical approach differ?The initial 18 months of the first multi-disciplinary regional Pulmonary Arterial Hypertension Clinic in Australia.Pharmacoeconomic evidence of bosentan for pulmonary arterial hypertension.An update on the evaluation and management of pulmonary hypertension in scleroderma.Treatment of pulmonary arterial hypertension in connective tissue disease.N-TproBNP as biomarker in systemic sclerosis.Early Mortality in a Multinational Systemic Sclerosis Inception Cohort.Autopsy case of systemic sclerosis with severe pulmonary hypertension.

P2860

Q24618843-EA1FAE10-78E8-4B02-B369-C81AB4FB651D Q24681558-124C7DB9-8450-4AEB-9AC2-6A7224DD5CE5 Q30490484-5B31BB90-B959-436B-BB90-C9074B1D8365 Q33950086-97602634-680F-4731-99B7-DC7413A24DA5 Q33965825-98BAB8B9-D635-41BA-80C4-DB0479E4738A Q34032884-7AFD7C8B-749F-47DA-B3D4-E7D22B788B49 Q34167350-46452163-624D-4D10-B1DE-E83C589D6ABC Q34417785-80A90DA3-3A3B-4AF1-B8ED-D99A3B449DAC Q34732817-2D257DC6-40C6-4A4B-91C1-60C360B0C7B8 Q35557424-199F036A-9DB5-4FAF-80DF-F4D30475C280 Q35637949-042FE882-0D23-472F-8302-9A8580679EF8 Q35792872-183F8AB1-60B4-4D8B-A8AA-5F2E7BFE48F3 Q35954516-757820EC-0021-476A-98B4-014C462E199F Q36075852-0A032292-B180-404C-B150-04F38A14D481 Q36293847-A040F9D7-672C-4BE8-8563-E56EEC667507 Q36328903-0F845409-D8F1-4F43-834E-254555061029 Q36543145-3F7B69D6-DC1A-4D31-A434-7186DC9A9346 Q36596818-846163DB-EB6C-46FD-80E6-D7593A560D70 Q36633190-41C073E3-59E7-4572-A80C-BF45BF7FDDBF Q36752821-8D6E4409-0AA8-4F4C-8E4E-9E1615C86BB7 Q36761364-0E0612A6-711B-4408-AEBC-A158234B11FE Q36765781-A878F70E-B2FA-4D79-B7CF-9299C324811F Q36795578-883155FB-D939-469A-81E9-136280273D46 Q36836706-7B4A4DB0-4851-4885-A24C-DCF95974506F Q36839875-6F1A285D-4C2A-45A6-86D5-55E6C11B5906 Q36930652-CAF8C6F5-DC90-4CEF-B55E-A7567F490C89 Q36930712-813519B0-6767-4B9C-AC12-E39FD3EDF42B Q37265423-86EA0E41-8173-4F78-9987-B1493C34A5EE Q37364799-90CAB1E7-D7B5-4117-B28B-AF317BAD9D2F Q37585187-9DB3C5DA-D797-44E0-B3A6-B0C18A7A3C0A Q37780253-B703961E-BF90-43F7-A6DF-BC0C4A771C79 Q37822722-83EBCE61-4312-44BC-A390-AE3E6A064B82 Q37845609-C53870DD-D66C-43F8-B69F-7D1CF82CC565 Q37857895-17B2DD8B-DCD6-443E-BF30-92D2422E1ED9 Q37889264-727FF54A-D61B-4836-9C11-B092C930B7A5 Q37973014-E6D97FC1-47D1-4669-94BC-8E668B43AC5D Q38012530-C8BD44E2-C4F9-4239-A654-E2715E20C870 Q38016375-79990FFE-B663-4639-A192-780A40F01245 Q40393079-133263EC-7071-4E65-8C31-33481C76020E Q40435628-2F10F326-0CF4-4E3B-AA4C-4534F20990ED

P2860

Systemic sclerosis associated pulmonary hypertension: improved survival in the current era.

http://www.wikidata.org/entity/Q35771091

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

2005年论文

@zh

2005年论文

@zh-cn

name

Systemic sclerosis associated ...... d survival in the current era.

@ast

Systemic sclerosis associated ...... d survival in the current era.

@en

type

label

Systemic sclerosis associated ...... d survival in the current era.

@ast

Systemic sclerosis associated ...... d survival in the current era.

@en

prefLabel

Systemic sclerosis associated ...... d survival in the current era.

@ast

Systemic sclerosis associated ...... d survival in the current era.

@en

P1433

Q35771091-D10738ED-1B4D-487C-9862-A7EE10D9EA3F

P1476

Q35771091-E27FC2A6-7A37-4042-B0BD-4215512763C6

P2093

Q35771091-18A0CFB2-00F4-4DC5-BF18-ED2B06B5DF9E

Q35771091-33975B17-1F8F-4D54-8470-30A3DE11F72F

Q35771091-6B69FAEE-8CCF-4F03-B6A2-4C1AF420AC25

Q35771091-758E5D41-8F89-4DB3-9B16-130C456C46D9

Q35771091-772B436E-9791-4D83-9F7F-EE6CEF39A266

Q35771091-980AC6C7-B17B-4D34-9DAF-BB061643D28D

Q35771091-9D75B845-0C54-4CE4-9922-2550B561F140

Q35771091-BE1A9038-D215-490A-98F9-85D9B0BFBA6C

Q35771091-D9881A15-615E-4B14-AE5E-E9174F73A186

P2860

Q35771091-134D1B62-2210-47E9-A487-32BCF9A33E7A

Q35771091-36A78088-D97B-4A7D-9716-CBAFE5958D97

Q35771091-3A358EAC-9963-4DBB-B803-5AF0A2E78AE2

Q35771091-5FDC5D30-6D74-447D-A5E3-077298F0C178

Q35771091-638EF5E1-A93A-448A-BFA5-7D33804166C2

Q35771091-63F7F129-8006-42D4-88A2-782646A3783F

Q35771091-709DC1D1-AA71-406C-8486-C2CB816AABA8

Q35771091-775B7CDB-33A5-4F2C-9C71-FC7C8FBE2BAE

Q35771091-79A9A8CB-9973-46A7-9ED4-77781E709BC5

Q35771091-80E9724D-E54C-4B11-9128-95DF0E1CF819

P304

Q35771091-B244FD5E-2908-410B-8B01-B1E090549B5D

P31

Q35771091-453C8174-CCF2-49B3-9EA8-E98C951EF798

P356

Q35771091-57526C5D-4790-4D37-B6E6-BFD3DEF39B86

P407

Q35771091-45B27E91-D448-426C-8AE0-90846FD3668A

P433

Q35771091-5FB580FB-8CC5-4E28-A767-A0CF87EC6C72

P478

Q35771091-259D8F69-454D-4E0D-BA26-7ACC3660F46A

P577

Q35771091-EEB2B295-B3BC-42FA-91F2-63B95C5F2D68

P5875

Q35771091-6D308EC7-907C-4724-BD14-E2E394E18BF9

P698

Q35771091-28C7DC78-0AD3-42C6-B6F0-74E1BEB64C0A

P932

Q35771091-091853E0-8BB2-4034-88CE-C500B7368CE5

P356

HRT.2005.069484

P1433

P1476

Systemic sclerosis associated ...... d survival in the current era.

@en

P2093

C Das

http://www.w3.org/2001/XMLSchema#string

C E Handler

http://www.w3.org/2001/XMLSchema#string

C J Smith

http://www.w3.org/2001/XMLSchema#string

C M Black

http://www.w3.org/2001/XMLSchema#string

C P Denton

http://www.w3.org/2001/XMLSchema#string

J Davar

http://www.w3.org/2001/XMLSchema#string

J G Coghlan

http://www.w3.org/2001/XMLSchema#string

M H Williams

http://www.w3.org/2001/XMLSchema#string

M R Akram

http://www.w3.org/2001/XMLSchema#string

P2860

Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial

Fibroblast matrix gene expression and connective tissue remodeling: role of endothelin-1.

Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial.

Inhaled iloprost for severe pulmonary hypertension.

ATS statement: guidelines for the six-minute walk test.

Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach.

Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease.

Cellular and molecular pathobiology of pulmonary arterial hypertension.

Pathologic assessment of vasculopathies in pulmonary hypertension.

Endothelin receptor antagonists in pulmonary arterial hypertension.

P304

926-932

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/HRT.2005.069484

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

92

http://www.w3.org/2001/XMLSchema#string

P577

2005-12-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7429615

http://www.w3.org/2001/XMLSchema#string

P698

16339813

http://www.w3.org/2001/XMLSchema#string

P932

1860719

http://www.w3.org/2001/XMLSchema#string